U.S. markets closed

Bruker Corporation (BRKR)

NasdaqGS - NasdaqGS Precio en tiempo real. Moneda en USD.
Añadir a la lista de seguimiento
67.00+1.20 (+1.82%)
Al cierre: 04:00PM EDT
67.41 +0.41 (+0.61%)
Fuera de horario: 07:54PM EDT

Bruker Corporation

40 Manning Road
Billerica, MA 01821
United States
978 663 3660
https://www.bruker.com

Sector(es)Healthcare
IndustriaMedical Devices
Empleados a tiempo completo9,707

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Frank H. Laukien Ph.D.Chairman, CEO & President2.53MN/D1960
Mr. Gerald N. HermanExecutive VP & CFO1.13MN/D1958
Dr. Mark R. Munch Ph.D.Corporate Executive VP and President of Bruker Nano Group & Corporate1.63MN/D1962
Mr. Juergen SregaPresident of Bruker CALID Group & Bruker Daltonics Division842.19kN/D1955
Dr. Falko Busse Ph.D.President of Bruker BioSpin Group945.18kN/D1967
Mr. Justin Joseph WardSenior Director of Investor Relations & Corporate DevelopmentN/DN/DN/D
Mr. J. Brent Alldredge J.D.General Counsel & SecretaryN/DN/D1975
Dr. Burkhard Prause Ph.D.President and CEO of Bruker Energy & Supercon Technologies, Inc.595.96kN/D1967
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Gestión corporativa

La calificación ISS Governance QuickScore de Bruker Corporation a partir del 1 de octubre de 2024 es 5. Las puntuaciones principales son Auditoría: 7; Junta: 7; Derechos del accionista: 4; Compensación: 3.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.